- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Melanoma
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Nivolumab; ipilimumab – November 2019
Nivolumab and Ipilimumab: nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL, Injection concentrate for I.V. infusion 200 mg in 40 mL; Opdivo® Yervoy®
Last updated
6 March 2020
